# PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06616532/  
OnCo record `nct06616532` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing PM8002 in small-cell lung cancer and non-small-cell lung cancer, active and no longer recruiting.

## Summary

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06616532, led by Biotheus, and active but no longer recruiting on the registry. Official title: A Multicenter, Open-lable, Randomised Phase III Study of PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer. Planned enrolment is 404 participants (estimated). The study started in 2024-11-13 and primary completion is expected in 2027-01-25. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06616532
- Phase: 3
- Setting: A Multicenter, Open-lable, Randomized Phase III Study of PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
- Sponsor: Biotheus
- Enrolled: 404

## Sources

- ClinicalTrials.gov NCT06616532: https://clinicaltrials.gov/study/NCT06616532

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [PM8002](https://onco.cc/drugs/pm8002/)
- companies: [BioNTech](https://onco.cc/companies/biontech/)

---
JSON: https://onco.cc/api/v1/entities/nct06616532.json